Stockscreener 앱 받기
92.21
0.96%
0.88
시장 영업 전:
94.33
2.12
+2.30%
전일 마감가:
$91.33
열려 있는:
$91.7
하루 거래량:
3.27M
Relative Volume:
0.64
시가총액:
$53.09B
수익:
$6.30B
순이익/손실:
$1.07B
주가수익비율:
50.10
EPS:
1.8406
순현금흐름:
$1.09B
1주 성능:
-2.29%
1개월 성능:
+7.25%
6개월 성능:
+8.32%
1년 성능:
+17.02%
1일 변동 폭
$90.69
$92.25
1주일 범위
$90.69
$96.29
52주 변동 폭
$72.30
$96.29
에드워즈라이프사이언시스 Stock (EW) Company Profile
명칭
Edwards Lifesciences Corp
전화
(949) 250-2500
주소
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
에드워즈라이프사이언시스 Stock (EW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-01 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-12-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-10-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-10-07 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-04-24 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | 업그레이드 | Stifel | Hold → Buy |
| 2025-01-16 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-09-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-31 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | Truist | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-03-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-02-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-28 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-03-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | 다운그레이드 | Bernstein | Outperform → Underperform |
| 2023-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 개시 | Mizuho | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-29 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 개시 | Truist | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-03-16 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-27 | 재확인 | Citigroup | Buy |
| 2022-01-27 | 재확인 | Evercore ISI | Outperform |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | Stifel | Buy |
| 2022-01-27 | 재확인 | UBS | Neutral |
| 2021-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-12-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-30 | 재확인 | Deutsche Bank | Hold |
| 2021-07-30 | 재확인 | Jefferies | Buy |
| 2021-07-30 | 재확인 | Morgan Stanley | Overweight |
| 2021-07-30 | 재확인 | Oppenheimer | Outperform |
| 2021-07-30 | 재확인 | Stifel | Buy |
| 2021-07-30 | 재확인 | UBS | Neutral |
| 2021-07-30 | 재확인 | Wells Fargo | Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-04-05 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-11 | 재확인 | Canaccord Genuity | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Underperform |
| 2020-04-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Outperform |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-09-23 | 개시 | Piper Jaffray | Overweight |
| 2019-07-24 | 재확인 | BofA/Merrill | Buy |
| 2019-03-18 | 재확인 | Canaccord Genuity | Buy |
| 2019-01-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 개시 | Deutsche Bank | Hold |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-10-02 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
모두보기
에드워즈라이프사이언시스 주식(EW)의 최신 뉴스
Edwards Lifesciences stock reflects steady growth prospects in cardiovascular care - ad-hoc-news.de
Edwards Lifesciences stands out as US agency eyes broader access for heart valve device - MSN
Edwards Lifesciences CVP sells $56,762 in company stock - Investing.com UK
Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Form 4 Edwards Lifesciences Corp For: 10 July By Investing.com - Investing.com India
Edwards Lifesciences CVP sells $56,762 in company stock By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) CFO receives stock, performance unit and option grants - Stock Titan
Edwards Lifesciences (NYSE: EW) CVP exercises stock options and sells 619 shares - Stock Titan
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
TRiCares Announces Initiation of TRICURE US IDE Pivotal Study for Topaz Tricuspid Valve Replacement System - GlobeNewswire Inc.
Edwards Lifesciences highlights structural heart portfolio as investors track long-term growth - ad-hoc-news.de
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE:EW) Valve Data Keeps Healthcare Focus - Kalkine Media
Edwards Lifesciences focuses on heart valve growth as US cardiac demand stays solid - ad-hoc-news.de
The Edwards SAPIEN 3 Ultra ValvePrecision Transcatheter Option For US Heart Patients - AD HOC NEWS
Form 4 Edwards Lifesciences Corp For: 7 July By Investing.com - Investing.com Nigeria
Edwards Lifesciences’ SWOT analysis: stock gains momentum on market share opportunity - Investing.com
Edwards Lifesciences (EW) executive has shares withheld for tax on vesting - Stock Titan
Edwards Lifesciences highlights structural heart portfolio as investors track long-term growth prosp - ad-hoc-news.de
Edwards Lifesciences Investors Seek 1st OK For $39M Deal - Law360
EWEdwards Lifesciences Corp Latest SEC Filings - Finviz
EW Maintained by Evercore ISI Group -- Price Target Raised to $1 - GuruFocus
Edwards Lifesciences Corp (EW): Analyst Consensus Points to Growth Potential in the Medical Device Sector - DirectorsTalk Interviews
Edwards Lifesciences stock leans on its core heart valve business - ad-hoc-news.de
Law firm investigates Edwards Lifesciences offi... - Pluang
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders? - marketscreener.com
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MSN
TD Cowen Names Edwards Lifesciences as Top Medical Device Pick By Investing.com - Investing.com Nigeria
TD Cowen Names Edwards Lifesciences as Top Medical Device Pick - Investing.com
Edwards Lifesciences stock hits 52-week high at 92.94 USD By Investing.com - Investing.com Nigeria
Edwards Lifesciences stock hits 52-week high at 92.94 USD - Investing.com
What You Need To Know Ahead of Edwards Lifesciences' Earnings Release - Yahoo Finance
Edwards Lifesciences highlights heart valve portfolio as investors watch long-term growth - AD HOC NEWS
Insider Sell Alert: Daniel Lippis Sells Shares of Edwards Lifesc - GuruFocus
Edwards Lifesciences CVP Daniel Lippis sells $56k in stock By Investing.com - Investing.com Nigeria
Form 4 Edwards Lifesciences Corp For: 30 June By Investing.com - Investing.com Canada
TAX MANAGED MULTI CAP GROWTH PORTFOLIO's Edwards Lifesciences Corp(EW) Holding History - GuruFocus
Edwards Lifesciences CVP Daniel Lippis sells $56k in stock - Investing.com
Edwards Lifesciences (NYSE: EW) exec sells 619 shares under 10b5-1 plan - Stock Titan
BTIG Adjusts Price Target on Edwards Lifesciences to $110 From $100, Maintains Buy Rating - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Edwards Lifesciences (EW) Gains FDA Approval for Ecliptis System - GuruFocus
Edwards Lifesciences Wins FDA Clearance for ECLIPTIS LAA System - Medical Device and Diagnostic industry
Edwards Lifesciences Corporation(NYSE: EW) added to Russell Midcap Value Benchmark - marketscreener.com
Edwards Lifesciences: The Heart of OC Medtech - Orange County Business Journal
Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic - MedTech Dive
Edwards Lifesciences presents fresh trial data, shares supported by robust S&P 500 positioning - AD HOC NEWS
Edwards Lifesciences Corporation $EW Shares Sold by OLD National Bancorp IN - MarketBeat
Edwards Lifesciences Reports New Clinical Trial Updates - Orange County Business Journal
에드워즈라이프사이언시스 (EW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.49%
0.00%
자본화:
|
볼륨(24시간):